CN116036018B

CN116036018B - Foam type hair growth liquid and preparation method thereof

Info

Publication number: CN116036018B
Application number: CN202211582818.XA
Authority: CN
Inventors: 曹青日; 李雪程; 霍明伟; 孙薇
Original assignee: Suzhou University
Current assignee: Suzhou University
Priority date: 2022-12-08
Filing date: 2022-12-08
Publication date: 2024-12-20
Anticipated expiration: 2042-12-08
Also published as: WO2024119694A1; CN116036018A

Abstract

The invention discloses a foam type hair growth liquid and a preparation method thereof, wherein the foam type hair growth liquid comprises, by mass, 10% -55% of a surfactant, 0.1% -1% of an oily substance, 1% -50% of a cosolvent, 0.05% -1% of a bacteriostatic agent, 0.1% -12% of an active drug and 30% -80% of water. The preparation method of the foam type hair growth liquid comprises the following steps of (1) uniformly mixing a surfactant, an oily substance, a cosolvent and a bacteriostatic agent, then adding an active drug, heating to fully dissolve the active drug to obtain an oil phase containing the drug, and (2) dropwise adding the oil phase containing the drug into an aqueous phase to obtain the foam type hair growth liquid. The nanoemulsion foam type hair growth liquid prepared by the method has the advantages of simple preparation method and controllable quality, and the prepared nanoemulsion foam type hair growth liquid can promote skin penetration of medicines, achieves better medicine treatment effect and has smaller toxic and side effects.

Description

Foam type hair growth liquid and preparation method thereof

Technical Field

The invention relates to the technical field of pharmaceutical preparations, in particular to foam type hair growth liquid and a preparation method thereof.

Background

Seborrheic alopecia is an androgen-dependent hereditary hair loss disease, whose onset may be related to endocrine dysfunction, genetics, fungal infection, and inflammation. At present, research on seborrheic alopecia is carried out to a molecular level, new therapeutic drugs are also continuously appeared, and the trend of combined development of traditional Chinese medicine and western medicine is presented. The drugs commonly used in clinic at present for treating alopecia mainly comprise two kinds of finasteride and minoxidil.

Finasteride is a type II 5 alpha-reductase selective inhibitor and can reduce the conversion of testosterone into dihydrotestosterone with stronger binding force with a receptor, thereby weakening the influence of androgens on alopecia. Minoxidil is a nonspecific drug for treating alopecia, and is an FDA-approved topical drug for treating seborrheic alopecia. The mechanism of minoxidil for preventing and treating alopecia is to open potassium ion channel, inhibit calcium ion inflow, reduce the inhibition of epidermal growth factor to hair growth, promote proliferation and differentiation of hair follicle epithelial cells, up regulate vascular endothelial cell growth factor, improve local blood supply, etc.

The finasteride preparation on the market is an oral solid preparation at present, and is effective only after being continuously taken for more than 1 year, and can cause male fetal external genital development deformity and sexual side effects when being used for pregnant women. In addition, prolonged oral administration of finasteride may also cause increased body hair, breast development, reduced sexual function, elevated cholesterol levels, mood disorders, and the like. In the market, minoxidil is mostly a liniment or gel for external use, and the purpose of treating alopecia is achieved by expanding blood vessels. However, when minoxidil liniment is used, the liquid has strong fluidity, is easy to be sprayed on the face, and is not easy to cause hirsutism in time, while minoxidil gel is affected by the form of the dosage form, the drug concentration is far lower than other dosage forms, and the treatment effect is limited. To further enhance the therapeutic effect, finasteride and minoxidil are used in combination to prepare topical products, but most of these co-applied products have no actual synergistic effect. For example, CN103596550a discloses a composition for topical application for preventing hair loss and promoting hair growth, i.e., a composition for topical application comprising a 5α -reductase inhibitor and minoxidil, for preventing hair loss and promoting hair growth, which has the problems of a longer treatment course, etc., although the therapeutic effect is improved compared to the administration of a single 5α -reductase inhibitor or minoxidil, because the 5α -reductase inhibitor has a larger side effect, and thus the content of 5α -reductase inhibitor in the topically applied dosage form is reduced. CN105658223a discloses a composition for reducing hair loss and/or increasing hair regrowth comprising minoxidil, finasteride and a prostaglandin analogue, a topically applicable spray for reducing hair loss and increasing hair regrowth in a human subject is prepared, but no significant synergy is achieved.

In addition, resveratrol is a polyphenol plant antitoxin and has the functions of resisting oxidization, inflammation and apoptosis. Recent experiments have shown that resveratrol has the effects of promoting hair growth and prolonging the anagen phase of hair follicles, and is mainly characterized by accelerating the entry into anagen phase and delaying the progression (Hair Growth-Promoting Effect of Resveratrol in Mice,Human Hair Follicles and Dermal Papilla Cells), of catagen phase, even at low concentrations, can mediate proliferation of dermal papilla cells, protecting them from oxidative stress. Resveratrol is expected to be a potential drug for preventing and treating alopecia. Glucocorticoids, such as dexamethasone, are also one of the most common, reliable and effective methods for treating alopecia areata at present, and the administration methods include external application, local injection and systemic administration. The mechanism of action is mainly related to anti-inflammatory and immunosuppression.

Based on the fact that the existing pharmaceutical preparation for treating alopecia has large side effect and poor effect, the need for providing the hair growth liquid with good curative effect and small side effect is urgent.

Disclosure of Invention

The invention aims to solve the technical problems of providing foam type hair growth liquid and a preparation method thereof, wherein finasteride, minoxidil, resveratrol or dexamethasone with different mechanisms are used in combination and are prepared into nano emulsion foam type hair growth liquid, the process is simple, the quality is controllable, the prepared foam agent spray does not flow, the foam is stable, the foam agent spray can be fully contacted with focus for a long time, the deep penetration of a medicine to scalp is promoted, the residence time of the medicine in a human body is prolonged, the medicine effect is better, the generation of a foam film can reduce chemical stimulation and physical stimulation to a dosing part, and the toxic and side effect is smaller.

In order to solve the technical problems, the invention provides the following technical scheme:

The first aspect of the invention provides a foam type hair growth liquid, which comprises, by mass, 10% -55% of a surfactant, 0.1% -1% of an oily substance, 1% -50% of a cosolvent, 0.05% -1% of a bacteriostatic agent, 0.1% -12% of an active drug and 30% -80% of water, wherein the oily substance is fat, and the active drug is one or more of finasteride, minoxidil, resveratrol and dexamethasone.

Further, when the foam-type hair growth liquid contains finasteride, the mass ratio of the finasteride in the foam-type hair growth liquid is 0.1% -1%, when the foam-type hair growth liquid contains minoxidil, the mass ratio of the minoxidil in the foam-type hair growth liquid is 1% -5%, when the foam-type hair growth liquid contains resveratrol, the mass ratio of the resveratrol in the foam-type hair growth liquid is 1% -5%, and when the foam-type hair growth liquid contains dexamethasone, the mass ratio of the dexamethasone in the foam-type hair growth liquid is 0.1% -1%.

Further, the surfactant is caprylic capric polyethylene glycol glyceride and/or polyglycerol-3 oleate.

Further, the cosolvent is propylene glycol, and the introduction of propylene glycol is found to improve the solubility of minoxidil.

Further, the bacteriostat is phenoxyethanol and/or methyl parahydroxybenzoate.

Further, the foam type hair growth liquid comprises, by mass, 10% -40% of caprylic/capric polyethylene glycol glyceride, 0.1% -15% of polyglycerol-3 oleate, 0.1% -1% of medium chain triglyceride, 1% -50% of propylene glycol, 0.01% -1% of phenoxyethanol, 0.01% -1% of methylparaben, 0.1% -12% of an active drug and 30% -80% of water, wherein the active drug is one or more of finasteride, minoxidil, resveratrol and dexamethasone.

Further, the foam type hair growth liquid also comprises 0.01% -1% of essence by mass percent.

Further, the foam type hair growth liquid comprises, by mass, 24% of caprylic-capric acid polyethylene glycol glyceride, 2.7% of polyglycerol-3 oleate, 0.5% of medium chain triglyceride, 4% of propylene glycol, 0.5% of phenoxyethanol, 0.1% of methyl parahydroxybenzoate, 0.1% -12% of active medicine, 0.1% of essence and the balance of water, wherein the active medicine is one or more of finasteride, minoxidil, resveratrol and dexamethasone.

Further, the foam type hair growth liquid preferably comprises 0.1% -5% of active drugs in percentage by mass.

Further, the active medicine contains minoxidil, and the mass ratio of minoxidil in the foam type hair growth liquid is 2%.

Further, the active medicine further comprises one or more of finasteride, resveratrol and dexamethasone, wherein the mass ratio of the finasteride in the foam-type hair growing liquid is 0.25%, the mass ratio of the resveratrol in the foam-type hair growing liquid is 1.2%, and the mass ratio of the dexamethasone in the foam-type hair growing liquid is 0.1%.

The second aspect of the invention provides a preparation method of the foam type hair growth liquid according to the first aspect, which comprises the following steps:

(1) Uniformly mixing a surfactant, an oily substance, a cosolvent and a bacteriostatic agent, adding an active drug, and heating to fully dissolve the active drug to obtain an oil phase containing the drug;

(2) And (3) dripping the oil phase containing the medicine into the water phase to obtain the foam type hair growth liquid.

Further, in the step (1), the temperature of the mixing is 40-70 ℃.

Further, in the step (1), the heating temperature is 40-70 ℃.

Further, in step (2), the aqueous phase is water or an aqueous solution formed by other water-soluble additives and water.

Further, in the step (2), the oil phase containing the drug is dropped into the water phase at a constant speed under stirring.

Further, when the foam-type hair tonic contains essence, the essence is added after the oil phase containing the medicine is dripped into the water phase.

Further, the foam type hair growth liquid is a nano emulsion.

The nanoemulsion is a transparent or semitransparent system with the particle size of 10-100 nm, low viscosity, isotropy, thermodynamics and dynamics stability, which is formed by a water phase, an oil phase, a surfactant and a cosurfactant according to a proper proportion. The nanoemulsion can increase the solubility of insoluble drugs, improve the structure and permeability of skin horny layer, and promote the transdermal absorption of the drugs and enhance the drug effect, so that the concentration of the drugs in the hair tonic can be reduced while the curative effect is ensured, and the side effect of the drugs is reduced. The prepared nanoemulsion foaming agent is introduced into air through a specific administration device to generate a large amount of foam dosage forms, and the generation of a foam film can reduce chemical stimulation and physical stimulation to administration parts, so that the practicability and the compliance are better.

Compared with the prior art, the invention has the beneficial effects that:

1. The invention provides a foam hair tonic which contains one or more medicines with different mechanisms and can promote hair growth or inhibit hair loss, the nanoemulsion can improve the solubility of insoluble medicines, and simultaneously improve the permeability of the medicines in the skin horny layer and promote the percutaneous absorption of the medicines; in addition, the nanoemulsion prepared by the invention can be used for generating a large amount of foam dosage forms by introducing air through a specific drug delivery device, and the generation of a foam film can reduce chemical stimulation and physical stimulation to a drug delivery part, so that the practicability and the compliance are better.

2. Compared with other dosage forms, the nano emulsion foam hair growth liquid provided by the invention has the advantages that the spray does not flow, the foam is stable, the nano emulsion foam hair growth liquid can be fully contacted with a focus for a long time, the deep penetration of the medicine to scalp is promoted, the residence time of the medicine in a body is prolonged, the medicine effect is better, and the toxic and side effects are smaller.

3. The invention also provides a preparation method of the nanoemulsion foam hair growth liquid, which is simple in preparation method, controllable in quality, low in cost and suitable for industrial mass production.

Drawings

FIG. 1 is an external view of hair tonic of examples 1-8 in order from left to right;

FIG. 2 is a foam appearance after extrusion by a hydrodynamic pump for hair growth in examples 1-8;

FIG. 3 is a graph showing the effect of foam hair tonic and commercially available minoxidil tincture on the back hair growth of mice;

FIG. 4 is a graph showing the results of statistical analysis of the hair growth promoting effect of foam-type hair tonic and commercially available minoxidil tincture on the back of mice.

Detailed Description

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. The term "and/or" as used herein includes any and all combinations of one or more of the associated listed items.

The present invention will be further described with reference to the accompanying drawings and specific examples, which are not intended to be limiting, so that those skilled in the art will better understand the invention and practice it.

Example 1

The embodiment relates to preparation of a foam type hair growth liquid, wherein the medicine component in the foam type hair growth liquid is minoxidil, and the mass ratio of the medicine component in the foam type hair growth liquid is 2%.

The preparation process is as follows:

(1) 2.4g of caprylic-capric acid polyethylene glycol glyceride, 0.27g of polyglycerol-3 oleate, 0.05g of medium chain triglyceride, 0.4g of propylene glycol, 0.05g of phenoxyethanol and 0.01g of methyl parahydroxybenzoate are respectively weighed and mixed under the condition of 60 ℃ by heating and stirring for 5min, then 0.2g of minoxidil is added into the mixed solution, and the mixture is heated and stirred at the same temperature for 0.5h to be fully dissolved, so as to obtain an oil phase containing the medicine;

(2) And (3) dropwise adding the oil phase containing the medicine prepared in the step (1) into 6.61g of water under the condition of stirring at normal temperature, and adding 0.01g of essence to uniformly mix to obtain the foam type hair growing liquid.

Example 2

The embodiment relates to preparation of a foam type hair growing liquid, wherein the medicine component in the foam type hair growing liquid is finasteride, and the mass ratio of the medicine component in the foam type hair growing liquid is 0.25%.

The preparation process is as follows:

(1) 2.4g of caprylic-capric acid polyethylene glycol glyceride, 0.27g of polyglycerol-3 oleate, 0.05g of medium chain triglyceride, 0.4g of propylene glycol, 0.05g of phenoxyethanol and 0.01g of methyl parahydroxybenzoate are respectively weighed and mixed under the condition of 60 ℃ by heating and stirring for 5min, then 0.025g of finasteride is added into the mixed solution, and the mixture is heated and stirred at the same temperature for 0.5h to be fully dissolved, so as to obtain an oil phase containing the medicine;

(2) And (3) dropwise adding the oil phase containing the medicine prepared in the step (1) into 6.785g of water under the condition of stirring at normal temperature, and adding 0.01g of essence to uniformly mix to obtain the foam type hair growing liquid.

Example 3

The embodiment relates to preparation of a foam type hair growth liquid, wherein the medicine component in the foam type hair growth liquid is resveratrol, and the mass ratio of the medicine component in the foam type hair growth liquid is 1.2%.

The preparation process is as follows:

(1) 2.4g of caprylic-capric acid polyethylene glycol glyceride, 0.27g of polyglycerol-3 oleate, 0.05g of medium chain triglyceride, 0.4g of propylene glycol, 0.05g of phenoxyethanol and 0.01g of methyl parahydroxybenzoate are respectively weighed and mixed under the condition of 60 ℃ by heating and stirring for 5min, then 0.12g of resveratrol is added into the mixed solution, and the mixed solution is heated and stirred at the same temperature for 0.5h to be fully dissolved, so that an oil phase containing a medicine is obtained;

(2) And (3) dropwise adding the oil phase containing the medicine prepared in the step (1) into 6.69g of water under the condition of stirring at normal temperature, and adding 0.01g of essence to uniformly mix to obtain the foam type hair growing liquid.

Example 4

The embodiment relates to preparation of a foam-type hair-growing liquid, wherein the medicine components in the foam-type hair-growing liquid are finasteride and minoxidil, the mass ratio of the finasteride in the foam-type hair-growing liquid is 0.25%, and the mass ratio of the minoxidil in the foam-type hair-growing liquid is 2%.

The preparation process is as follows:

(1) 2.4g of caprylic-capric acid polyethylene glycol glyceride, 0.27g of polyglycerol-3 oleate, 0.05g of medium chain triglyceride, 0.4g of propylene glycol, 0.05g of phenoxyethanol and 0.01g of methyl parahydroxybenzoate are respectively weighed and mixed under the condition of 60 ℃ under heating and stirring for 5min, then 0.025g of finasteride and 0.2g of minoxidil are added into the mixed solution, and the mixture is heated and stirred at the same temperature for 0.5h to be fully dissolved, so that an oil phase containing medicines is obtained;

(2) And (3) dropwise adding the oil phase containing the medicine prepared in the step (1) into 6.585g of water under the condition of stirring at normal temperature, and adding 0.01g of essence to uniformly mix to obtain the foam type hair growing liquid.

Example 5

The embodiment relates to preparation of a foam type hair growing liquid, wherein the medicine components in the foam type hair growing liquid are minoxidil and resveratrol, the mass ratio of the minoxidil in the foam type hair growing liquid is 2%, and the mass ratio of the resveratrol in the foam type hair growing liquid is 1.2%.

The preparation process is as follows:

(1) 2.4g of caprylic-capric acid polyethylene glycol glyceride, 0.27g of polyglycerol-3 oleate, 0.05g of medium chain triglyceride, 0.4g of propylene glycol, 0.05g of phenoxyethanol and 0.01g of methyl parahydroxybenzoate are respectively weighed and mixed under the condition of 60 ℃ under heating and stirring for 5min, then 0.2g of minoxidil and 0.12g of resveratrol are added into the mixed solution, and the mixture is heated and stirred at the same temperature for 0.5h to fully dissolve the mixture, so as to obtain an oil phase containing the medicine;

(2) And (3) dropwise adding the oil phase containing the medicine prepared in the step (1) into 6.49g of water under the condition of stirring at normal temperature, and adding 0.01g of essence to uniformly mix to obtain the foam type hair growing liquid.

Example 6

The embodiment relates to preparation of a foam type hair growth liquid, wherein the medicine components in the foam type hair growth liquid are finasteride and resveratrol, the mass ratio of finasteride in the foam type hair growth liquid is 0.25%, and the mass ratio of resveratrol in the foam type hair growth liquid is 1.2%.

The preparation process is as follows:

(1) 2.4g of caprylic-capric acid polyethylene glycol glyceride, 0.27g of polyglycerol-3 oleate, 0.05g of medium chain triglyceride, 0.4g of propylene glycol, 0.05g of phenoxyethanol and 0.01g of methyl parahydroxybenzoate are respectively weighed and mixed under the condition of 60 ℃ under heating and stirring for 5min, then 0.025g of finasteride and 0.12g of resveratrol are added into the mixed solution, and the mixture is heated and stirred at the same temperature for 0.5h to be fully dissolved, so that an oil phase containing a medicament is obtained;

(2) And (3) dropwise adding the oil phase containing the medicine prepared in the step (1) into 6.665g of water under the condition of stirring at normal temperature, and adding 0.01g of essence to uniformly mix to obtain the foam type hair growing liquid.

Example 7

The embodiment relates to preparation of a foam type hair growing liquid, wherein the medicine components in the foam type hair growing liquid comprise minoxidil, finasteride and resveratrol, wherein the mass ratio of minoxidil in the foam type hair growing liquid is 2%, the mass ratio of finasteride in the foam type hair growing liquid is 0.25%, and the mass ratio of resveratrol in the foam type hair growing liquid is 1.2%.

The preparation process is as follows:

(1) 2.4g of caprylic-capric acid polyethylene glycol glyceride, 0.27g of polyglycerol-3 oleate, 0.05g of medium chain triglyceride, 0.4g of propylene glycol, 0.05g of phenoxyethanol and 0.01g of methyl parahydroxybenzoate are respectively weighed and mixed under the condition of 60 ℃ by heating and stirring for 5min, then 0.2g of minoxidil, 0.025g of finasteride and 0.12g of resveratrol are added into the mixed solution, and the mixed solution is heated and stirred for 0.5h at the same temperature to be fully dissolved, so that an oil phase containing medicines is obtained;

(2) And (3) dropwise adding the oil phase containing the medicine prepared in the step (1) into 6.465g of water under the condition of stirring at normal temperature, and adding 0.01g of essence to uniformly mix to obtain the foam type hair growing liquid.

Example 8

The embodiment relates to preparation of a foam-type hair-growing liquid, wherein the medicine components in the foam-type hair-growing liquid comprise minoxidil, dexamethasone and resveratrol, the mass ratio of the minoxidil in the foam-type hair-growing liquid is 2%, the mass ratio of the dexamethasone in the foam-type hair-growing liquid is 0.1%, and the mass ratio of the resveratrol in the foam-type hair-growing liquid is 1.2%.

The preparation process is as follows:

(1) 2.4g of caprylic-capric acid polyethylene glycol glyceride, 0.27g of polyglycerol-3 oleate, 0.05g of medium chain triglyceride, 0.4g of propylene glycol, 0.05g of phenoxyethanol and 0.01g of methyl parahydroxybenzoate are respectively weighed and mixed under the condition of 60 ℃ by heating and stirring for 5min, then 0.2g of minoxidil, 0.01g of dexamethasone and 0.12g of resveratrol are added into the mixed solution, and the mixture is heated and stirred for 0.5h at the same temperature to be fully dissolved, so that an oil phase containing a medicament is obtained;

(2) And (3) dropwise adding the oil phase containing the medicine prepared in the step (1) into 6.48g of water under the condition of stirring at normal temperature, and adding 0.01g of essence to uniformly mix to obtain the foam type hair growing liquid.

Performance test and application

1. Nanoemulsion particle size test

The foam type hair growth liquid prepared in the above examples 1 to 8 is shown in fig. 1, each hair growth liquid is clear and transparent, a proper amount of the foam type hair growth liquid prepared in the above examples 1 to 8 is taken, particle size and particle size distribution index (PDI) are measured by a nano-particle size and Zeta potential analyzer, the test is carried out 3 times, the average value is taken, and the test result is shown in the following table 1:

TABLE 1 particle size and PDI of foam hair tonic prepared in different examples

Sample of	Average particle diameter.+ -. SD/nm	PDI
			Example 1	9.55±0.501	0.166±0.015
Example 2	11.39±0.182	0.174±0.033
			Example 3	42.21±1.025	0.427±0.043
Example 4	11.81±0.051	0.134±0.041
			Example 5	63.72±1.12	0.452±0.006
Example 6	48.61±0.390	0.402±0.01
			Example 7	77.99±0.710	0.318±0.011
Example 8	73.38±0.764	0.314±0.002

As can be seen from the table, the particle size of the foam type hair growth liquid prepared by the method is smaller than 100nm, and the nano emulsion is formed.

2. Foam morphology evaluation

The foam type hair growth liquid prepared in the examples 1-8 is taken in the same amount, and is extruded in a culture dish by a power pump to form foam, the foam form of each sample is shown in the figure 2, the ejectors of each sample do not flow, the foam is fine, uniform and stable, the foam duration is further recorded, the foam duration is measured for 3 times, the average value is taken, and the test results are shown in the following table 2:

TABLE 2 foam duration of foam type hair tonic prepared in different examples

Examples	Foam duration.+ -. SD/min
		1	7.14±1.40
2	7.81±1.12
		3	14.10±1.27
4	7.50±1.08
		5	14.80±0.65
6	14.22±4.79
		7	7.44±1.75
8	11.30±1.94

As is clear from the above table, the foam extruded from the foam type hair tonic prepared in each example can last at least 5 minutes and even last more than 15 minutes.

3. Evaluation of pharmacodynamics

Male C57BL/6 mice were selected for 4, anesthetized with diethyl ether, shaved on their backs and dehaired with depilatory cream. The androgenic alopecia mice model was established by daily topical application of testosterone ethanol solution. Mice were randomly divided into 4 groups, a blank control group, a positive control group and an experimental group, respectively. The positive control group was coated with commercially available 5% minoxidil tincture, and the experimental group was coated with the foam hair tonic prepared in example 4 and example 5, and the administration was started 1 time per day for 2 weeks on the first day after depilation. The back hair growth of the mice was recorded daily and the results are shown in figure 3.

As can be seen from fig. 3, the back skin of the mice treated with the foam-type hair tonic grew significantly more and denser hair at day 14 than the back skin of the mice of the control group. The foam-type hair tonic treated mice had slower pre-growth phase than the commercially available 5% minoxidil tincture treated mice, but it was seen that the hair tonic effect was comparable between the foam-type hair tonic and the commercially available 5% minoxidil tincture by the appearance of the back of the mice at day 21 (see fig. 3) and the measurement of hair length (see fig. 4). It is shown that the foam type hair tonic can promote the growth of the hair of mice. Compared with 5% minoxidil, 2% minoxidil compound foam nanoemulsion has smaller side effects and lower occurrence rate of adverse events.

The above-described embodiments are merely preferred embodiments for fully explaining the present invention, and the scope of the present invention is not limited thereto. Equivalent substitutions and modifications will occur to those skilled in the art based on the present invention, and are intended to be within the scope of the present invention. The protection scope of the invention is subject to the claims.

Claims

1. A foam-type hair-growth liquid, characterized in that, by mass percentage, the foam-type hair-growth liquid comprises the following components: 10% to 40% of caprylic capric macrogol glyceride, 0.1% to 15% of polyglycerol-3 oleate, 0.1% to 1% of medium-chain triglycerides, 1% to 50% of propylene glycol, 0.01% to 1% of phenoxyethanol, 0.01% to 1% of methyl paraben, 0.1% to 12% of an active drug, and 30% to 80% of water, wherein the active drug is selected from one or more of finasteride, minoxidil, resveratrol, and dexamethasone; the foam-type hair-growth liquid is a nanoemulsion.

2. A foamy hair growth liquid according to claim 1, characterized in that, by mass percentage, the foamy hair growth liquid further comprises 0.01% to 1% of essence.

3. The foamy hair-growth liquid according to claim 2, characterized in that, in terms of mass percentage, the foamy hair-growth liquid is composed of the following components: 24% of caprylic capric macrogol glycerides, 2.7% of polyglycerol-3 oleate, 0.5% of medium-chain triglycerides, 4% of propylene glycol, 0.5% of phenoxyethanol, 0.1% of methyl paraben, 0.1% to 12% of active drugs, 0.1% of essence, and the remainder is water; the active drugs are selected from one or more of finasteride, minoxidil, resveratrol, and dexamethasone.

4. A foam-type hair-growth liquid according to claim 3, characterized in that the active drug comprises minoxidil, and the mass proportion of minoxidil in the foam-type hair-growth liquid is 2%.

5. A foam-type hair growth liquid according to claim 4, characterized in that the active drug further comprises one or more of finasteride, resveratrol, and dexamethasone; the mass proportion of finasteride in the foam-type hair growth liquid is 0.25%, the mass proportion of resveratrol in the foam-type hair growth liquid is 1.2%, and the mass proportion of dexamethasone in the foam-type hair growth liquid is 0.1%.

6. A method for preparing the foam type hair growth liquid according to any one of claims 1 to 5, characterized in that it comprises the following steps:

(1) A surfactant, an oily substance, a cosolvent and an antibacterial agent are mixed uniformly, and then an active drug is added, and heated to fully dissolve the active drug to obtain an oil phase containing the drug; the surfactant is caprylic acid capric acid macrogol glyceride and polyglycerol-3 oleate, the oily substance is a medium chain triglyceride, the cosolvent is propylene glycol, and the antibacterial agent is phenoxyethanol and methyl paraben;

(2) Adding the oil phase containing the drug dropwise into the water phase to obtain the foamy hair growth liquid.

7. The preparation method according to claim 6, characterized in that in step (1), the heating temperature is 40-70°C.